Parkinson’s disease is a neurodegenerative disorder that is common in older people and is highly associated with depression, anxiety, apathy, psychosis, cognitive impairment, imbalance and sleep disturbances. These patients have an increased risk of fracture compared to the general population. Comprehensive searches of databases are performed to identify reviews about the risk of fractures in this disease. Parkinson’s patients are at increased risk for low bone mineral density due to the effect of drugs, Parkinson’s disease and age factor, leading to an increased risk of falling down and fractures, especially in the hip. So, improved and innovative treatments with the focus on minimizing inadvertent bone resorption with anti-Parkinson’s disease medication will be highly effective in reducing fear of the disease and providing the patient with a better quality of life.
Camacho-Soto, A., Gross, A., Nielsen, S.S., Miller, A.N., Warden, M.N., Salter, A. and Racette, B.A. (2020) Fractures in the Prodromal Period of Parkinson’s Disease. Neurology, 94, e2448-e2456. https://doi.org/10.1212/WNL.0000000000009452
Caobi, A., Dutta, R.K., Garbinski, L.D., Esteban-Lopez, M., Ceyhan, Y. andre, M., Manevski, M., Ojha, C.R., Lapierre, J., Tiwari, S. and Parira, T. (2020) The Impact of CRISPR-Cas9 on Age-Related Disorders: From Pathology to Therapy. Aging and Disease, 11, 895. https://doi.org/10.14336/AD.2019.0927
Connolly, B.S. and Lang, A.E. (2014) Pharmacological Treatment of Parkinson Disease: A Review. JAMA: Journal of the American Medical Association, 311, 1670-1683. https://doi.org/10.1001/jama.2014.3654
Coomber, R., Alshameeri, Z., Masia, A.F., Mela, F. and Parker, M.J. (2017) Hip Fractures and Parkinson’s Disease: A Case Series. Injury, 48, 2730-2735. https://doi.org/10.1016/j.injury.2017.08.042
Fullard, M.E. and Duda, J.E. (2020) A Review of the Relationship between Vitamin D and Parkinson’s Disease Symptoms. Frontiers in Neurology, 11, Article No. 454. https://doi.org/10.3389/fneur.2020.00454
Agustn Pavón, C. and Isalan, M. (2014) Synthetic Biology and Therapeutic Strategies for the Degenerating Brain: Synthetic Biology Approaches can Transform Classical Cell and Gene Therapies to Provide New Cures for Neurodegenerative Diseases. Bioessays, 36, 979-990. https://doi.org/10.1002/bies.201400094
Sponer, P., Kucera, T., Grinac, M., Bezrouk, A. and Waciakowski, D. (2017) The Outcomes of Total Hip Replacement in Patients with Parkinson’s Disease: Comparison of the Elective and Hip Fracture Groups. Parkinson’s Disease, 2017, Article ID: 1597463. https://doi.org/10.1155/2017/1597463
Alhakamy, N.A., Curiel, D.T. and Berkland, C.J. (2021) The Era of Gene Therapy: From Preclinical Development to Clinical Application. Drug Discovery Today, 26, 1602-1619. https://doi.org/10.1016/j.drudis.2021.03.021
LeWitt, P.A., Kymes, S. and Hauser, R.A. (2020) Parkinson Disease and Orthostatic Hypotension in the Elderly: Recognition and Management of Risk Factors for Falls. Aging and Disease, 11, 679. https://doi.org/10.14336/AD.2019.0805
Angulo, J., Fleury, V., P, J.A., Zullino, D., Krack, P., Foundation, P. and York, M. (2019) Shame in Parkinson’s Disease: A Review. Journal of Parkinson’s Disease, 9, 489-499. https://doi.org/10.3233/JPD-181462
Henderson, E.J., Lyell, V., Bhimjiyani, A., Amin, J., Kobylecki, C. and Gregson, C.L. (2019) Management of Fracture Risk in Parkinson’s: A Revised Algorithm and Focused Review of Treatments. Parkinsonism & Related Disorders, 64, 181-187. https://doi.org/10.1016/j.parkreldis.2019.03.021
Yan, S., Fu, W., Wang, C., Mao, J., Liu, B., Zou, L. and Lv, C. (2020) Association between Sedentary Behavior and the Risk of Dementia: A Systematic Review and Meta-Analysis. Translational Psychiatry, 10, 112. https://doi.org/10.1038/s41398-020-0799-5
Zach, H., Dirkx, M., Bloem, B.R. and Helmich, R.C. (2015) The Clinical Evaluation of Parkinson’s Tremor. Journal of Parkinson’s Disease, 5, 471-474. https://doi.org/10.3233/JPD-150650
Arbouw, M.E.L., Movig, K.L.L., van Staa, T.P., Egberts, A.C.G., Souverein, P.C. and de Vries, F. (2011) Dopaminergic Drugs and the Risk of Hip or Femur Fracture: A Population-Based Case-Control Study. Osteoporosis International: A Journal Established as Result of Cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 22, 2197-2204. https://doi.org/10.1007/s00198-010-1455-3
Bliemel, C., Oberkircher, L., Eschbach, D.A., Lechler, P., Balzer-Geldsetzer, M., Ruchholtz, S. and Buecking, B. (2015) Impact of Parkinson’s Disease on the Acute Care Treatment and Medium-Term Functional Outcome in Geriatric Hip Fracture Patients. Archives of Orthopaedic and Trauma Surgery, 135, 1519-1526. https://doi.org/10.1007/s00402-015-2298-3
Pouwels, S., Bazelier, M.T., Boer, A., Weber, W.E.J., Neef, C., Cooper, C. and Vries, F. (2013) Risk of Fracture in Patients with Parkinson’s Disease. Osteoporosis International, 24, 2283-2290. https://doi.org/10.1007/s00198-013-2300-2
Lisk, R., Watters, H. and Yeong, K. (2017) Hip Fracture Outcomes in Patients with Parkinson’s Disease. Clinical Medicine, 17, s20. https://doi.org/10.7861/clinmedicine.17-3-s20
Kalilani, L., Asgharnejad, M., Palokangas, T. and Durgin, T. (2016) Comparing the Incidence of Falls/Fractures in Parkinson’s Disease Patients in the US Population. PLOS ONE, 11, e0161689. https://doi.org/10.1371/journal.pone.0161689
Lyell, V., Henderson, E., Devine, M. and Gregson, C. (2015) Assessment and Management of Fracture Risk in Patients with Parkinson’s Disease. Age and Ageing, 44, 34-41. https://doi.org/10.1093/ageing/afu122
Schlienger, R.G. and Meier, C.R. (2003) Effect of Selective Serotonin Reuptake Inhibitors on Platelet Activation. American Journal of Cardiovascular Drugs, 3, 149-162. https://doi.org/10.2165/00129784-200303030-00001
Bondon-Guitton, E., Perez-Lloret, S., Bagheri, H., Brefel, C., Rascol, O. and JL, M. (2011) Drug-Induced Parkinsonism: A Review of 17 Years’ Experience in a Regional Pharmacovigilance Center in France. Movement Disorders, 26, 2226-2231. https://doi.org/10.1002/mds.23828
Konno, T., Siuda, J. and Wszolek, Z.K. (2016) Genetics of Parkinson’s Disease: A Review of SNCA and LRRK2. Wiadomosci lekarskie (Warsaw, Poland: 1960), 69, 328-332.
Buttery, P.C. and Barker, R.A. (2014) Treating Parkinson’s Disease in the 21st Century: Can Stem Cell Transplantation Compete? Journal of Comparative Neurology, 522, 2802-2816. https://doi.org/10.1002/cne.23577
Wild, E.J. and Tabrizi, S.J. (2014) Targets for Future Clinical Trials in Huntington’s Disease: What’s in the Pipeline? Movement Disorders, 29, 1434-1445. https://doi.org/10.1002/mds.26007
Elkouzi, A., Vedam-Mai, V., Eisinger, R.S. and Okun, M.S. (2019) Emerging Therapies in Parkinson’s Disease—Repurposed Drugs and New Approaches. Nature Reviews Neurology, 15, 204-223. https://doi.org/10.1038/s41582-019-0155-7
Elsayed, I., Martinez-Carrasco, A., Cornejo-Olivas, M. and Bandres-Ciga, S. (2021) Mapping the Diverse and Inclusive Future of Parkinson’s Disease Genetics and Its Widespread Impact. Genes, 12, 1681. https://doi.org/10.3390/genes12111681
Sudhakar, V. and Richardson, R.M. (2019) Gene Therapy for Neurodegenerative Diseases. Neurotherapeutics, 16, 166-175. https://doi.org/10.1007/s13311-018-00694-0
Siddiqi, B. and Koemeter-Cox, A. (2021) A Call to Action: Promoting Diversity, Equity, and Inclusion in Parkinson’s Research and Care. Journal of Parkinson’s Disease, 11, 905-908. https://doi.org/10.3233/JPD-212593
LeWitt, P.A., Rezai, A.R., Leehey, M.A., Ojemann, S.G., Flaherty, A.W., Eskandar, E.N., Kostyk, S.K., Thomas, K., Sarkar, A., Siddiqui, M.S., Tatter, S.B., Schwalb, J.M., Poston, K.L., Henderson, J.M., Kurlan, R.M., Richard, I.H., Van Meter, L., Sapan, C.V, During, M.J. and Feigin, A. (2011) AAV2-GAD Gene Therapy for Advanced Parkinson’s Disease: A Double-Blind, Sham-Surgery Controlled, Randomized Trial. The Lancet Neurology, 10, 309-319. https://doi.org/10.1016/S1474-4422(11)70039-4
Lanteigne, A., Sheu, Y.H., Stürmer, T., Pate, V., Azrael, D., Swanson, S.A. and Miller, M. (2015) Serotonin-Norepinephrine Reuptake Inhibitor and Selective Serotonin Reuptake Inhibitor Use and Risk of Fractures: A New-User Cohort Study among Us Adults Aged 50 Years and Older. CNS Drugs, 29, 245-252. https://doi.org/10.1007/s40263-015-0231-5
Parmar, M., Grealish, S. and Henchcliffe, C. (2020) The Future of Stem Cell Therapies for Parkinson Disease. Nature Reviews Neuroscience, 21, 103-115. https://doi.org/10.1038/s41583-019-0257-7
Liu, Z. and Cheung, H.H. (2020) Stem Cell-Based Therapies for Parkinson Disease. International Journal of Molecular Sciences, 21, 1-17. https://doi.org/10.3390/ijms21218060
Venkataramana, N.K., Kumar, S.K.V., Balaraju, S., Radhakrishnan, R.C., Bansal, A., Dixit, A., Rao, D.K., Das, M., Jan, M., Gupta, P.K. and Totey, S.M. (2010) Open-Labeled Study of Unilateral Autologous Bone-Marrow-Derived Mesenchymal Stem Cell Transplantation in Parkinson’s Disease. Translational Research, 155, 62-70. https://doi.org/10.1016/j.trsl.2009.07.006
Sponer, P., Kuera, T., Grinac, M., Bezrouk, A. and Waciakowski, D. (2017) The Results of Total Hip Replacement in Patients with Parkinson’s Disease: Comparison of the Elective and Hip Fracture Groups. Parkinson’s Disease, 2017, 181-187.
Devnani, P. (2013) Treatment of REM Behaviour Disorder—An Evidence Based Review. Sleep Medicine, 14, e20-e22. https://doi.org/10.1016/j.sleep.2013.11.013
Nystrom, H., Nordstrom, A. and Nordstrom, P. (2016) Risk of Injurious Fall and Hip Fracture up to 26 Years before Diagnosing Parkinson’s Disease: Nested Case-Control Studies in a Nationwide Cohort. PLoS Medicine, 13, e1001954. https://doi.org/10.1371/journal.pmed.1001954
Lazennec, J.Y., Kim, Y. and Pour, A.E. (2018) Total Hip Arthroplasty in Patients with Parkinson’s Disease: Improved Outcomes with Dual Mobility Implants and Cementless Fixation. The Journal of Arthroplasty, 33, 1455-1461. https://doi.org/10.1016/j.arth.2017.11.062